BioRestorative Therapies's ROE % for the quarter that ended in Mar. 2026 was -510.06%. BioRestorative Therapies's PB Ratio for the quarter that ended in Mar. 2026 was 2.23.
BioRestorative Therapies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -228.73%.
BioRestorative Therapies ROE % Adjusted to Book Value Related Terms
BioRestorative Therapies ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for BioRestorative Therapies's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies ROE % Adjusted to Book Value Chart
STU:9OF vs CVKD, JSPR, APRE: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, BioRestorative Therapies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -228.73% mean?
BioRestorative Therapies (STU:9OF) has a ROE % Adjusted to Book Value of -228.73% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioRestorative Therapies and its competitors.
Is BioRestorative Therapies' ROE % Adjusted to Book Value too high?
BioRestorative Therapies' current ROE % Adjusted to Book Value is -228.73%. Overall, BioRestorative Therapies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' ROE % Adjusted to Book Value compare to CVKD and JSPR?
BioRestorative Therapies' ROE % Adjusted to Book Value of -228.73% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current ROE % Adjusted to Book Value is -228.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (STU:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.27, compared to a current price of €0.32 — trading 75.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -228.73%. BioRestorative Therapies' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioRestorative Therapies (STU:9OF), the current ROE % Adjusted to Book Value is -228.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (STU:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.32 is trading 75.1% below its estimated GF Value™ of €1.27.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for STU:9OF:
ROE % Adjusted to Book Value: -228.73%
GF Value™: €1.27 vs. price of €0.32 (75.1% below fair value)
No single metric tells the full story. See the STU:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
60GF Score
Get the complete analysis for STU:9OF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9OF has been successfully added to your 
